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Abstract
Registry data are important for monitoring the impact of new therapies on treatment algorithms and outcomes, and for guiding clinical
decision making in multiple myeloma (MM). This observational study analyzed real-world data from patients in the Population-based
HAematological Registry for Observational Studies who were treated for symptomatic MM from 2008 to 2013 in the Netherlands. The
primary endpoint was overall survival (OS) from initiation of ﬁrst-line treatment. Secondary endpoints included OS and progression-free
survival per treatment line, treatment patterns, and treatment response. Between 2008 and 2013, 917, 583, 283, and 139 patients had
initiated ﬁrst, second, third, and fourth treatment lines, respectively. Thalidomide-based regimenswere themost frequently used ﬁrst-line
treatment (66%); bortezomib- and lenalidomide-based regimens were most often used in the second line (41% and 27%, respectively).
ThemedianOS (95%conﬁdence interval) ranged from37.5months (34.8–41.8months) in the ﬁrst line to 9.2months (6.2–12.3months)
in the fourth line. Univariate analyses showed that survival beneﬁts were most apparent in younger patients (65 vs>65 years). These
analyses provide important real-world information on treatment patterns and outcomes in patients with MM.
Introduction
Multiple myeloma (MM) accounts for 1% of all cancers, and in
2012 the number of new cases in Europe was estimated at
38,900.1,2 In the Netherlands, the incidences of MM in 2012
were 6.6 and 4.0 cases per 10,000 people for men and women,
respectively.2 There have been improvements in diagnosis, early
intervention, treatment, and supportive care for patients with
MM over the past 15 years, and as a result, patient outcomes in
Europe have improved signiﬁcantly.3,4 Data from the Dutch
Cancer Registry show that 5-year overall survival (OS) improved
substantially in patients with MM diagnosed in 2004 to 2009
compared with those diagnosed in 1989 to 1993.5 Although
Funding/support: PHAROS is ﬁnancially supported by ZonMW 2009-2012 (No. 80-82500-98-01007) and through unrestricted grants from: Bayer, Bristol-Myers
Squibb, Celgene, GlaxoSmithKline, Mundipharma, Novartis, Roche, and Sanoﬁ.
Funding for this research was provided by Amgen (Europe) GmbH. Data analysis and statistical support were provided by the Institute for Medical Technology
Assessment at Erasmus University Rotterdam, the Netherlands and were funded by Amgen (Europe) GmbH. Medical writing support was provided by Liz Hartﬁeld of
Oxford PharmaGenesis, Oxford, UK and was funded by Amgen (Europe) GmbH.
Disclosure: Author contributions and potential conﬂicts of interest: SGRV, HMB, LD, SG-M, and JBD conceived and designed the study; SG-M, JBD, PS, CAU, SGRV,
HMB, and SD were involved in data acquisition; all authors were involved in the interpretation of the analyses and writing of the paper. All authors approved the ﬁnal
version of the paper and take responsibility for its content.
SGRV: no conﬂicts of interest; HMB: research support from Bristol-Myers Squibb; SD: research support from Amgen; SG-M, LD, and JBD: employees of Amgen and
hold Amgen stock; CAU: research support from Astellas, Bayer, Bristol-Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Janssen-Cilag, MSD, Mundipharma, Novartis,
Roche, Therakos, and Sanoﬁ; PS: research support and honoraria from Amgen, Celgene, Janssen, Karyopharm, SkylineTx, and Takeda.
Supplemental Digital Content is available for this article.
1Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
2Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
3Comprehensive Cancer Organisation, Utrecht, The Netherlands
4Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands
5Amgen (Europe) GmbH, Zug, Switzerland
6Amgen Ltd, Uxbridge, UK
7Amgen BV, Breda, The Netherlands.
Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access article distributed
under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the
work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
HemaSphere (2018) 2:4(e45)
Received: 11 December 2017 / Received in ﬁnal form: 29 March 2018 / Accepted: 13 April 2018
Citation: Verelst SGR, Blommestein HM, De Groot S, Gonzalez-McQuire S, DeCosta L, de Raad JB, Uyl-de Groot CA, Sonneveld P. Long-term Outcomes in
Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS).
HemaSphere, 2018;2:4. http://dx.doi.org/10.1097/HS9.0000000000000045
Powered by EHA
Article
1
survival rates have improved over time, relapse rates and
mortality remain high, indicating a need for more effective
treatment options. Until 2014, the immunomodulatory drugs
(IMiDs) thalidomide6 and lenalidomide,7 and the proteasome
inhibitor bortezomib8 were the mainstays of treatment in Europe.
It is important to understand how these treatment patterns and
agents have impacted patient outcomes in routine clinical
practice.
While clinical trials are considered the gold standard for
assessing novel treatment options, they often have strict inclusion
criteria that exclude, for example, patients with comorbidities
and/or a poor health status. Registries differ from clinical trials in
that they collect real-world data on all patients and are therefore
likely to reﬂect the characteristics of the general patient
population. Disease-speciﬁc registries such as the Population-
based HAematological Registry for Observational Studies
(PHAROS) in the Netherlands are valuable sources of real-
world evidence. PHAROS was established in 2010 and has
collected treatment data from adult patients (aged ≥18 years)
diagnosed with hematological malignancies (including MM) in
the Netherlands from January 2004 onward.9 These data provide
information on treatment patterns and patient outcomes in daily
clinical practice for a broad patient population often not captured
in clinical trials.
Previously, data from PHAROS have been used to describe and
evaluate patterns of treatment sequences and the impact of
sequence ordering on progression-free survival (PFS) and OS for
nontransplant-eligible patients diagnosed between 2004 and
2011,5,10,11 as well as to assess cost-effectiveness.9,12 In this
study, data from patients who received initial treatment for
symptomatic MM between January 1, 2008 and December 31,
2013 were analyzed to assess real-world treatment patterns and
long-term patient outcomes in the Netherlands. The routine use
of thalidomide-based regimens as well as the approval of
bortezomib and lenalidomide during this period may have
impacted treatment patterns and patient outcomes over time;
therefore, this time frame was selected for analysis.
Results
Patient and disease characteristics
The total study population in PHAROS included 1887 patients
with MM diagnosed from 2004 onward, of whom 917 had
initiated ﬁrst-line treatment in or after 2008 and who comprised
the ﬁrst treatment line analysis set; 583, 283, and 139 patients
had initiated second, third, and fourth treatment lines in or after
2008, respectively.
Considering trial participation (data not shown), 15% of all
patients in the ﬁrst-line treatment cohort participated in a clinical
trial at ﬁrst line (138 out of 917 patients). Out of the 538 patients
who had initiated a second treatment line, 47 participated in a
clinical trial at that line (8%). In the later-line treatment cohorts,
trial participation was 3% for third-line treatment (9 patients out
of 283) and 8% for fourth-line treatment (11 patients out of 139).
Baseline patient characteristics at the initiation of a treatment
line were generally similar across treatment lines (Table 1), with
the exception of the year of diagnosis, which was related to the
inclusion criteria. The median age at treatment initiation was 70
years in the ﬁrst treatment line, 71 years in the second and third
treatment lines, and 72 years in the fourth treatment line. Over
one-third of patients had more than 1 comorbidity at diagnosis
(35–42% across treatment lines). In the ﬁrst-line treatment
cohort, 18% of patients had undergone high-dose therapy with
stem cell transplantation (SCT) as their initial treatment. In the
second treatment line cohort, 23% of the patients had received
this high-dose treatment with SCT in either the current or
previous treatment line. For patients included in the third and
fourth treatment line cohort, this was 25% and 21%,
respectively.
Treatment patterns
In the ﬁrst treatment line, thalidomide-based regimens were most
frequently used (66%), followed by bortezomib-based regimens
(15%) (Table 2). The proportion of patients receiving a regimen
containing thalidomide in the second, third, and fourth treatment
lines was 19%, 14%, and 5%, respectively.
In the second treatment line, bortezomib- and lenalidomide-
based regimens were used most often (41% and 27%,
respectively). In subsequent treatment lines, lenalidomide-based
regimens were most common (44% and 34% in the third and
fourth treatment lines, respectively), followed by bortezomib-
based regimens (28% and 29%, respectively).
Patient outcomes
The median follow-up for OS from the ﬁrst treatment line was
62.4 months (95% conﬁdence interval [CI]: 60.6–64.3 months).
The median OS was 37.5 months (95% CI: 34.8–41.8 months),
19.7 months (95% CI: 17.2–22.9 months), 13.9 months (95%
CI: 10.5–16.6 months), and 9.2 months (95% CI: 6.2–12.3
months) for patients receiving ﬁrst, second, third, and fourth
treatment lines in or after 2008, respectively (Fig. 1).
A similar trend was also observed for PFS. The median follow-
up for PFS from the ﬁrst treatment line was 38.8 months (95%
CI: 36.4–44.0 months). The median PFS in the ﬁrst treatment line
was 18.0 months (95% CI: 16.3–18.9 months). In subsequent
treatment lines, the median PFS decreased to 8.9 months (95%
CI: 7.9–9.7 months), 6.4 months (96% CI: 5.5–7.2 months), and
4.7 months (95% CI: 3.8–5.6 months) following the initiation of
the second, third, and fourth treatment lines, respectively (Fig. 2).
The depth of response also decreased at later lines of treatment
(Table 3). In the ﬁrst treatment line, 69% of patients achieved a
partial response (PR) or better, and 12% of patients had a
complete response (CR) or stringent CR (sCR). In the fourth
treatment line, only 34% of patients achieved a PR or better, and
only 1% had achieved a CR or sCR. It should be noted, however,
that the percentage of patients for whom the level of response was
unknown increased in later lines. Almost one-quarter of patients
(24%) achieved a very good PR in the ﬁrst treatment line, while in
the second, third, and fourth treatment lines, the rate had
decreased to 14%, 9%, and 6%, respectively. Concurrently, the
proportion of patients with progressive disease increased from
7% in the ﬁrst treatment line to 13%, 19%, and 17% in the
second, third, and fourth treatment lines, respectively.
Age at treatment initiation and survival outcomes
In the ﬁrst treatment line, the median OS in patients aged 65 years
or younger at the initiation of treatment was double that of those
who were older at the initiation of treatment (64.6 months [95%
CI: 53.2 months to not reached [NR] vs 31.9 months [95% CI:
29.1–35.4months]) (Table 4). ThemedianOSwas also longer for
younger patients (aged 65 years) than for older patients (aged
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Table 1
Patient and Disease Characteristics for Patients Initiating a Line of Treatment in 2008 to 2013 at the Start of Each Treatment Line
First Treatment Line
(N=917)
Second Treatment Line
(N=583)
Third Treatment Line
(N=283)
Fourth Treatment Line
(N=139)
Median age, years (range) 70 (36–93) 71 (38–93) 71 (39–94) 72 (42–90)
Sex, n (%)
Female 415 (45) 258 (44) 120 (42) 63 (45)
Male 502 (55) 325 (56) 163 (58) 76 (55)
WHO performance status at diagnosis, n (%)
0 or 1 657 (72) 415 (71) 206 (73) 101 (73)
2–4 108 (12) 64 (11) 27 (10) 12 (9)
Missing 152 (17) 104 (18) 50 (18) 26 (19)
Mean b2 microglobulin level, mg/L (SD) 5.6 (5.2) 4.6 (4.1) 5.2 (5.0) 4.7 (3.6)
Missing, n (%) 239 (26) 272 (47) 159 (56) 84 (60)
b2 microglobulin level, n (%)
<2.5 mg/L 140 (15) 97 (17) 26 (9) 10 (7)
≥2.5 mg/L 538 (59) 214 (37) 98 (35) 45 (32)
Missing 239 (26) 272 (47) 159 (56) 84 (60)
Mean creatinine level, mmol/L (SD) 138.2 (138.6) 117.9 (104.0) 116.0 (102.7) 105.7 (59.1)
Missing, n (%) 11 (1) 12 (2) 8 (3) 4 (3)
Mean platelet count, 109/L (SD) 243.5 (101.2) 194.9 (88.7) 174.8 (87.7) 171 (105.9)
Missing, n (%) 14 (2) 12 (2) 5 (2) 2 (1)
ISS stage at diagnosis, n (%)
I 217 (24) 130 (22) 58 (20) 25 (18)
II 227 (25) 150 (26) 71 (25) 34 (24)
III 236 (26) 144 (25) 71 (25) 34 (24)
Missing 237 (26) 159 (27) 83 (29) 46 (33)
Year of diagnosis, n (%)
2004 1 (0) 12 (2) 10 (4) 8 (6)
2005 4 (0) 36 (6) 29 (10) 24 (17)
2006 10 (1) 47 (8) 34 (12) 13 (9)
2007 56 (6) 124 (21) 70 (25) 35 (25)
2008 278 (30) 136 (23) 67 (24) 32 (23)
2009 243 (26) 115 (20) 44 (16) 16 (12)
2010 236 (26) 87 (15) 25 (9) 11 (8)
2011 89 (10) 26 (4) 4 (1) 0 (0)
Comorbidities at diagnosis, n (%)
0–1 534 (58) 360 (62) 185 (65) 90 (65)
>1 383 (42) 223 (38) 98 (35) 49 (35)
Previous therapy, n (%)
Melphalan/prednisone-based NA 58 (10) 37 (13) 11 (8)
Thalidomide-based NA 368 (63) 74 (26) 25 (18)
Bortezomib-based NA 58 (10) 103 (36) 48 (35)
Lenalidomide-based NA 22 (4) 56 (20) 49 (35)
Pomalidomide/dexamethasone-based NA 0 (0) 0 (0) 1 (1)
Radiotherapy NA 1 (0) 0 (0) 0 (0)
Other NA 76 (13) 12 (5) 5 (4)
Unknown NA 0 (0) 1 (0) 0 (0)
(Prior) SCT, na (%)
Yes 161 (18) 135 (23) 71 (25) 29 (21)
No 756 (82) 448 (77) 212 (75) 110 (79)
ISS= International Staging System, NA=not applicable, SCT= stem cell transplantation, SD= standard deviation, WHO=World Health Organization.
a Number of patients who received high-dose therapy with SCT in the current or previous line.
Table 2
Treatment Regimens Used at Each Treatment Line for Patients Initiating a Line of Treatment During 2008 to 2013
First Treatment Line
(N=917)
Second Treatment Line
(N=583)
Third Treatment Line
(N=283)
Fourth Treatment Line
(N=139)
Treatment regimen, n (%)
Melphalan/prednisone-based 47 (5) 50 (9) 14 (5) 14 (10)
Thalidomide-based 608 (66) 109 (19) 39 (14) 7 (5)
Bortezomib-based 139 (15) 239 (41) 78 (28) 41 (29)
Lenalidomide-based 60 (7) 159 (27) 124 (44) 47 (34)
Pomalidomide/dexamethasone-based 0 (0) 0 (0) 1 (0) 0 (0)
Radiotherapy 1 (0) 0 (0) 0 (0) 0 (0)
Other 62 (7) 23 (4) 27 (10) 30 (22)
Unknown 0 (0) 1 (0) 0 (0) 0 (0)
(2018) 2:4 www.hemaspherejournal.com
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>65 years) in the second and fourth treatment lines, although the
CIs were overlapping, and patient numbers were low in later
treatment lines.
A longer median PFS was observed in younger patients (aged
65 years) than in those older than 65 years at the initiation of
ﬁrst-line treatment: 22.6 months (95% CI: 19.8–26.5 months)
versus 16.2 months (95%CI: 14.5–17.9 months). This difference
was not observed in later treatment lines (Table 5).
High-dose therapy with SCT and survival outcomes
For patients who received high-dose therapy with SCT (in the ﬁrst
treatment line), the median OS from initiation of the ﬁrst
treatment line was NR (95% CI: 70.4 months to NR) compared
with 32.2 months (95% CI: 29.2–35.5 months) for those who
had not received SCT in the ﬁrst line (Table 4). For patients who
were in the second treatment line and had ever received SCT (ie, in
the ﬁrst or second line), the median OS was 29.5 months (95%
CI: 19.9–40.1 months) compared with 17.7 months (95% CI:
15.8–21.4 months) for those who had not received SCT in the
ﬁrst or second treatment line. A trend for longer OS in patients
who had received SCT (in the previous or current line) was also
observed in the third line, but CIs were overlapping (14.5 months
[95% CI: 8.4–22.4 months] compared with 13.8 months [95%
CI: 10.5–16.6 months]). A longer OS was not observed in fourth-
line analyses (8.1 months [95% CI: 2.3–18.3 months] compared
with 9.4 months [95% CI: 6.2–12.8 months]).
In the ﬁrst line, PFS in patients who received SCT was double
that observed in those who did not receive SCT (32.0 months
[95% CI: 26.2–36.5 months] vs 15.2 months [95% CI: 13.6–
17.0 months]) (Table 5). The results of these analyses must
be interpreted with caution; older patients are less likely to be
eligible for SCT than younger patients, and this analysis was not
corrected for age.
Treatment type and survival outcomes
The median OS in the ﬁrst line was longer in patients receiving
IMiDs (41.8 months [95% CI: 37.1–47.1 months]) or protea-
some inhibitors (33.3 months [95%CI: 18.8–45.4 months]) than
in those receiving “other agents” (“other agents” included
alkylating agents such as cyclophosphamide and melphalan, or
other non-novel treatments) (24.1 months [95% CI: 15.3–31.3
months]). This trend was less pronounced in subsequent
treatment lines.
The median PFS was 18.6 months (95% CI: 17.4–19.8
months), 14.9 months (95% CI: 10.5–19.8 months), and 13.2
months (95% CI: 6.0–17.7 months) in patients receiving IMiDs,
proteasome inhibitors, and treatment with “other agents” in the
ﬁrst treatment line, respectively (Table 5). PFS was longer in
individuals treated with IMiDs or proteasome inhibitors than in
those who received “other agents” in the ﬁrst, second, and third
treatment lines.
Figure 1. Kaplan–Meier curves of overall survival from ﬁrst, second, third, and fourth treatment lines for patients initiating treatment during 2008 to
2013. CI=conﬁdence interval, OS=overall survival.
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International Staging System stage at diagnosis and
survival outcomes
Across all lines of treatment, patients with International Staging
System (ISS) stage I disease at diagnosis had a longer median OS
than those diagnosed with ISS stage II or III disease, ranging from
62.2 months (95% CI: 51.7 months to NR), 37.5 months (95%
CI: 33.3–46.1 months), and 30.3 months (95% CI: 22.8–36.8
months), respectively, in the ﬁrst treatment line, to 17.3 months
(95% CI: 7.7–22.3 months), 7.0 months (95% CI: 2.3–19.5
months), and 5.2 months (95% CI: 2.3–9.5 months), respective-
ly, in the fourth treatment line (Supplementary Table 1,
Supplemental Digital Content, http://links.lww.com/HS/A4).
A similar pattern was observed for median PFS, ranging from
22.0 months (ISS I) (95% CI: 20.1–26.2 months), 19.0 months
(ISS II) (95% CI: 17.6–20.8 months), and 13.0 months (ISS III)
(95% CI: 10.5–17.2 months) in the ﬁrst treatment line, to 5.6
months (ISS I) (95% CI: 3.8–7.8 months), 3.8 months (ISS II)
(95% CI: 2.3–8.0 months), and 3.5 months (ISS III) (95% CI:
2.0–5.0 months) in the fourth treatment line. In the third and
Table 3
Best Response by Treatment Line (per IMWG Criteria) for Patients Initiating a Line of Treatment in 2008 to 2013
First Treatment Line
(N=917)
Second Treatment Line
(N=583)
Third Treatment Line
(N=283)
Fourth Treatment Line
(N=139)
Best response, n (%)
ORRa 632 (69) 289 (50) 112 (40) 47 (34)
CR+b 106 (12) 35 (6) 7 (2) 2 (1)
VGPR 223 (24) 80 (14) 26 (9) 8 (6)
PR 303 (33) 174 (30) 79 (28) 37 (27)
MR 70 (8) 56 (10) 28 (10) 19 (14)
SD 56 (6) 42 (7) 31 (11) 14 (10)
PD 64 (7) 78 (13) 54 (19) 24 (17)
Unknown 95 (10) 118 (20) 58 (20) 35 (25)
CR= complete response, IMWG= International Myeloma Working Group, MR=minimal response, ORR= overall response rate, PD=progressive disease, PR=partial response, sCR= stringent complete
response, SD= stable disease, VGPR= very good partial response.
a ORR=PR or better.
b CR+sCR.
Figure 2. Kaplan–Meier curves of progression-free survival from ﬁrst, second, third, and fourth treatment lines for patients initiating treatment
during 2008 to 2013. CI=conﬁdence interval, PFS=progression-free survival.
(2018) 2:4 www.hemaspherejournal.com
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fourth treatment lines, the difference in PFS was smaller than in
the ﬁrst and second treatment lines (Supplementary Table 2,
Supplemental Digital Content, http://links.lww.com/HS/A4). For
both survival analyses, ISS stage was assessed at diagnosis only;
therefore, as patients progressed into later treatment lines, the
proportions of patients with low ISS stage decreased.
Discussion
This large, retrospective analysis of PHAROS revealed important
insights into real-world treatment patterns and outcomes in
patients with symptomatic MM in the Netherlands. Most
patients who initiated treatment from 2008 up to and including
2013 received thalidomide-based regimens in the ﬁrst treatment
line and bortezomib- or lenalidomide-based regimens in subse-
quent lines. This reﬂects the approval and reimbursement status
of these agents in Europe6–8 and the treatment recommendations
in the Netherlands13–16 at the time patients initiated treatment
lines.
Other studies have also assessed real-world treatment patterns
in patients withMM. Analysis of the AustrianMyeloma Registry
found that 48% of patients receiving ﬁrst-line treatment received
bortezomib, and 33% received an IMiD.4 In the second treatment
line, 48% of patients received bortezomib-based treatment, and
54% received an IMiD-based regimen.4 Similar results were
obtained from an analysis of data from the Czech Registry of
Monoclonal Gammopathies (RMG)17 and a large observational
patient chart review across 7 European countries.18 In PHAROS,
a larger proportion of patients received an IMiD in the ﬁrst
treatment line than in the Austrian and Czech registries. This
might partly be explained by the age of patients at diagnosis in the
different registries, the treatment guidelines in the Netherlands,
and the fact that thalidomide was the only agent that had been
approved for upfront treatment at the start of the study period;
bortezomib was approved later in the period. The use of IMiDs
and bortezomib in the second treatment line was similar across
the 3 registries.
There have been signiﬁcant increases in the use of bortezomib
over time, following its initial approval in Europe in 2004 and
subsequent label updates.8 It is likely that treatment patterns will
change in the coming years with the approval of next-generation
novel agents and treatment combinations. Since 2013 several new
agents have received regulatory approval in Europe, including
bendamustine,19 pomalidomide,20 panobinostat,21 carﬁlzo-
mib,22 ixazomib,23 daratumumab,24 and elotuzumab.25 It is
important to note that when interpreting the treatment patterns
seen in this analysis, reimbursement status and Dutch MM
guidelines play important roles in inﬂuencing treatment decisions
in the Netherlands. Only a small proportion of patients in the
PHAROS cohort may have received 1 or more of these next-
generation novel agents as part of a clinical trial or an early access
program. Furthermore, uptake of new agents may vary by region
Table 4
Overall Survival in Patients Initiating a Line of Treatment During 2008 to 2013, by Subgroup
First Treatment Line Second Treatment Line Third Treatment Line Fourth Treatment Line
N
Median OS, months
(95% CI) N
Median OS, months
(95% CI) N
Median OS, months
(95% CI) N
Median OS, months
(95% CI)
Age at treatment initiation, years
65 266 64.6 (53.2–NR) 159 24.8 (17.3–32.9) 82 10.5 (6.6–16.7) 31 9.2 (6.0–22.3)
>65 651 31.9 (29.1–35.4) 424 18.1 (16.5–22.0) 201 15.1 (11.1–18.2) 108 8.4 (6.0–12.7)
Received (previously) high-dose therapy with stem cell transplantation
Yes 161 NR (70.4–NR) 135 29.5 (19.9–40.1) 71 14.5 (8.4–22.4) 29 8.1 (2.3–18.3)
No 756 32.2 (29.2–35.5) 448 17.7 (15.8–21.4) 212 13.8 (10.5–16.6) 110 9.4 (6.2–12.8)
Type of (current) treatment
IMiDs 670 41.8 (37.1–47.1) 268 21.3 (17.1–24.8) 164 16.7 (12.8–21.7) 54 10.8 (6.1–17.7)
PIs 139 33.3 (18.8–45.4) 239 17.3 (14.8–21.4) 78 10.5 (6.9–15.1) 41 8.1 (4.2–16.5)
Othera 108 24.1 (15.3–31.3) 73 23.9 (16.7–31.0) 41 8.4 (4.5–15.9) 44 7.7 (1.9–13.2)
CI=conﬁdence interval, IMiD= immunomodulatory drug, NR=not reached, OS= overall survival, PI=proteasome inhibitor.
a Includes alkylating agents such as cyclophosphamide, vincristine, and melphalan, and other non-novel treatments.
Table 5
Progression-Free Survival in Patients Initiating a Line of Treatment in 2008 to 2013, by Subgroup
First Treatment Line Second Treatment Line Third Treatment Line Fourth Treatment Line
N Median PFS, months (95% CI) N Median PFS, months (95% CI) N Median PFS, months (95% CI) N Median PFS, months (95% CI)
Age at treatment initiation, years
65 266 22.6 (19.8–26.5) 159 8.8 (7.4–9.7) 82 5.6 (3.2–8.4) 30 4.4 (2.8–7.1)
>65 651 16.2 (14.5–17.9) 424 9.0 (7.8–10.0) 201 6.7 (5.5–7.7) 108 4.8 (3.8–5.9)
Received (previously) high-dose therapy with stem cell transplantation
Yes 161 32.0 (26.2–36.5) 135 9.5 (8.1–11.0) 71 6.8 (5.0–9.2) 29 3.8 (2.3–5.6)
No 756 15.2 (13.6–17.0) 448 8.6 (7.5–9.5) 212 6.0 (5.1–7.2) 109 4.8 (3.9–6.3)
Type of (current) treatment
IMiDs 670 18.6 (17.4–19.8) 268 9.3 (8.0–10.6) 164 6.9 (5.6–8.9) 53 5.5 (3.8–8.5)
PIs 139 14.9 (10.5–19.8) 239 8.8 (7.0–10.1) 78 5.6 (4.0–7.3) 41 5.2 (3.8–6.3)
Othera 108 13.2 (6.0–17.7) 73 7.1 (6.1–9.5) 41 5.9 (3.2–7.1) 44 3.2 (1.4–4.8)
CI=conﬁdence interval, IMiD= immunomodulatory drug, PFS=progression-free survival, PI=proteasome inhibitor.
a Includes alkylating agents such as cyclophosphamide, vincristine, and melphalan, and other non-novel treatments.
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and by clinic owing to local institutional practice9; therefore, an
updated analysis of PHAROS in the coming years is warranted.
In our study, the medians for OS and PFS from initiation of the
ﬁrst treatment line were approximately 3 and 1.5 years,
respectively. In subsequent treatment lines, the median OS and
PFS decreased substantially. In our study, patients were included
if they initiated a treatment line in 2008 or later, and so those in
later lines (ie, fourth line) may have received older agents in
previous treatment lines; this may have impacted on survival.
Nevertheless, decreased OS and PFS were also observed in the
European patient chart review of 7 countries18 and, although the
patient population was slightly different from that of PHAROS,
in an analysis of the Czech RMG.17
Our analyses of PHAROS revealed that age at treatment
initiation was associated with longer survival. This is supported
by ﬁndings from the Europe-wide EUROCARE-5 study in which
1-year age-relative OS decreased from 81.6% in patients aged
between 55 and 64 years to 59.7% in those older than 75 years.26
This may be explained by the fact that elderly patients are more
likely to have comorbidities, including renal impairment,
cardiovascular disease, diabetes, and deep vein thrombosis,
which can impact upon treatment decisions and patient
outcomes.27 We also found that patients who received an SCT
in a current or previous line had a longer medianOS and PFS than
those who had not received such treatment. In the Netherlands,
patients aged over 65 years are generally not eligible for high-
dose induction therapy and SCT (at least at the time of data
collection)13; therefore, their outcomes are likely to be worse than
those who are eligible for these treatments. Other population
studies have also demonstrated the beneﬁt of SCT on surviv-
al.28,29
In our study, patients with ISS stage I disease at diagnosis had a
longer OS and PFS than those diagnosed with ISS stage II or III
disease. This is supported by an analysis of the Greek Myeloma
Study group30 and in another study in which 5-year survival rates
were also found to be signiﬁcantly higher in patients with ISS
stage I disease than in those with stage II or III disease (52%,
42%, and 28%, respectively).3
In clinical trials, OS and PFS have been shown to be
considerably longer than those reported here (Table 6). In
addition, the proportion of patients in PHAROS achieving a CR
or sCR during the ﬁrst treatment line was only 12%, despite the
availability of a number of treatment options in clinical practice.
Although the inclusion and exclusion criteria of clinical trials
vary, in general, elderly patients and those who are in poor health
are often not included; hence, patients in clinical trials may not be
representative of the general population. This analysis of
PHAROS suggests that clinical trial data may not fully reﬂect
the real-world outcomes experienced by patients with symptom-
atic MM. Registry studies are therefore valuable because they
provide data on a heterogeneous patient population that more
accurately reﬂects patients encountered in clinical practice.9 In
Table 6
Survival Outcomes in Randomized Phase 2 and 3 Clinical Trials in the Frontline Setting (2008–2013)
Trial Treatment OS Other Survival Endpoints
VISTA32,33 Melphalan, prednisone, and bortezomib
vs melphalan and prednisone
Median OS: NR vs 43.1 months
3-year OS: 68.5% vs 54.0%
Median TTP: 24.0 months vs 16.6 months
(HR 0.48; P<0.001)
IFM 2005-0134 Bortezomib and dexamethasone vs
vincristine, doxorubicin, and
dexamethasone
Median OS: NR
3-year OS: 81.4% vs 77.4%
Median PFS: 36.0 months vs 29.7 months
HOVON-65/GMMG-HD435 Bortezomib, doxorubicin, and
dexamethasone vs vincristine,
doxorubicin, and dexamethasone
Median OS: NR
5-year OS: 61% vs 55%
Median PFS: 35 months vs 28 months
(HR 0.75; P=0.002)
Bortezomib, thalidomide, and
dexamethasone (GIMEMA)36
Bortezomib, thalidomide, and
dexamethasone vs thalidomide and
dexamethasone
3-year OS: 90% vs 88% Median TTP: NR vs 33 months
(HR 0.68; P=0.041)
Median PFS: NR vs 32 months
Bortezomib, thalidomide, and
dexamethasone (PETHEMA/GEM)37
Bortezomib, thalidomide, and
dexamethasone vs thalidomide and
dexamethasone
4-year OS: 74% vs 65% Median PFS: 56.2 months vs 28.2 months
(P=0.01)
Bortezomib, melphalan, prednisone,
and thalidomide38
Bortezomib, melphalan, prednisone,
and thalidomide vs bortezomib,
melphalan, and prednisone
5-year OS: 61% vs 51%
(HR 0.70; P=0.01)
Median PFS: 35.3 months vs 24.8 months
(HR 0.58; P<0.001)
HOVON-5039 Thalidomide, adriamycin, and
dexamethasone vs adriamycin and
dexamethasone
Median OS: 73 months vs 60 months Median EFS: 34 months vs 22 months
(HR 0.60; P<0.001)
Median PFS: 34 months vs 25 months
(HR 0.67; P<0.001)
Lenalidomide maintenance (IFM)40 Maintenance following ASCT with
lenalidomide or placebo
Median OS: NR
3-year OS: 80% vs 84%
Median PFS: 41 months vs 23 months
(HR 0.50; P<0.001)
Lenalidomide plus dexamethasone
(ECOG)41
Lenalidomide plus high- or low-dose
dexamethasone
Median OS: NR
1-year OS: 87% vs 96%
(P=0.0002)
2-year OS: 75% vs 87%
Median PFS: 19.1 months vs 25.3 months
(P=0.026)
Median TTP: 22.3 months vs 26.1 months
Lenalidomide, bortezomib, and
dexamethasone (IFM)42
Lenalidomide, bortezomib, and
dexamethasone induction and
consolidation
3-year OS: 100% 3-year PFS: 77%
ASCT= autologous stem cell transplantation, ECOG=Eastern Cooperative Oncology Group, EFS= event-free survival, GEM=Grupo Español de Mieloma, GIMEMA=Gruppo Italiano Malattie EMatologiche
dell’Adulto, GMMG=German Multicenter Myeloma Group, HOVON=Hemato-Oncologie voor Volwassenen Nederland, HR=hazard ratio, IFM= Intergroupe Francophone du Myélome, NR=not reached, OS=
overall survival, PETHEMA=Programa para el Estudio y la Terapéutica de las Hemopatías Malignas, PFS=progression-free survival, TTP= time-to-progression, VISTA=Velcade as initial standard therapy in
multiple myeloma.
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addition, in real-world practice, dose reductions and modiﬁca-
tions may be more likely than in clinical trials, which may impact
on survival.
This study has some limitations. First, if progression data were
not available, PFS was estimated using the start date of a new
treatment line as aproxy for the date of progression.Consequently,
PFS may have been overestimated in this analysis. Second, in some
instances, prognostic data, such as ISS stage at diagnosis, were
missing. Thus, proportions and outcomes should be interpreted
with caution. In general, registries could be improved if data could
be retrieved more easily and consistently from hospital records.
Third, owing to the advanced age of patients in PHAROS (median
age 71 years), the proportion of patients who had (previously)
undergone SCTwas lower thanmight be expected in a typicalMM
patient population, for example. The majority were elderly
patients, and during the study period these were not eligible for
SCT in theNetherlands if their agewas≥66years. Fourth, response
in real-world practice is not always measured and/or registered
regularly. As a consequence, a comparison with response as
measured in clinical trials may be biased.
This analysis of PHAROS provides important information on
treatment patterns and outcomes in patients with symptomatic
MM in real-world clinical practice in the Netherlands. Most
patients received IMiDs and proteasome inhibitors in the ﬁrst and
subsequent treatment lines. With each successive treatment line,
OS, PFS, and depth of response decreased. Despite the availability
of a number of treatment options, there remains a signiﬁcant
unmet need inMM. The data presented here will provide a useful
baseline with which the impact on survival of treatment patterns,
including new classes and combinations of agents, can be
compared. This information is important for patients, physicians,
and payers, and may help to inform treatment decisions in the
future.
Materials and methods
Study design
This was a noninterventional observational study using retro-
spective data from patient charts entered into PHAROS. The
study was approved by the ethical committee of the Erasmus
University Medical Center Rotterdam in the Netherlands (MEC-
2011-200). Patients were followed up from diagnosis until death,
loss to follow-up, or end of the observation period.
Data collection and study population
All patients diagnosed with MM (aged ≥18 years) in the
Netherlands between January 1, 2004 and December 31, 2011
are included in PHAROS. Data in PHAROS were obtained from
hospital records using standardized case report forms. Data were
collected between January 2010 and December 2013. OS data
were updated in December 2014 for this analysis. Information
was collected on diagnosis, comorbidities before and after
diagnosis, hospitalization, treatment, supportive care, treatment
response (assessed by the International Myeloma Working
Group criteria31), infections, treatment-related adverse events,
and post-treatment outcomes (including response status and
survival).
Patients were included in the analysis for each treatment line
that was initiated from 2008 up to and including 2013, and could
therefore be evaluated in more than 1 treatment line. We
performed the analyses per line. In the ﬁrst-line analysis, all
patient are includedwho had their ﬁrst line in 2008 or later. In the
second-line analysis, we included patients who had a second line
in or after 2008. These could be the same patients but also
patients who had a ﬁrst line in 2007 or earlier; the same applies
for the third line and fourth line.
Patients who were enrolled in clinical studies were included in
the analysis; patients with smouldering MM (SMM) at diagnosis
were excluded. Patients with SMMwho progressed to symptom-
atic MM were included from the time that they initiated MM
treatment.
Study endpoints
The primary endpoint of the study was OS from initiation of the
ﬁrst treatment line. The secondary endpoints included OS from
the second, third, and fourth line, PFS, best treatment response,
and treatment received, all by treatment line. We also performed
analyses of OS and PFS according to age, ISS stage at diagnosis,
(previous) SCT status, and treatment type.
Statistical analyses
No formal hypotheses were tested. Patients were grouped
according to treatment line. Patients who initiated a treatment
line between 2008 and 2013 were included for each treatment
line; therefore, individuals could have been included in multiple
treatment lines if these were initiated within the time frame of
these analyses. Patient characteristics and most commonly used
treatment regimens were summarized by line of therapy. A line of
therapy was considered as a period during which a patient was
treated with a speciﬁc antitumor regimen and the period
following treatment. A treatment line ended when a new
treatment was initiated, the end of the follow-up period was
reached, or the patient died. A new treatment line was deﬁned as
the initiation of treatment with a new antitumor drug regimen
when the patient appeared to be refractory, or after disease
progression. Changes in dosing were not considered a new line of
therapy. Retreatment with the same antitumor regimen was
considered a new line of therapy only if it followed disease
progression. Patients may have been diagnosed with MM (or
with SMM), but did not immediately start treatment; hence, it
was possible that there was a delay between diagnosis and ﬁrst-
line treatment initiation.
All analyses were descriptive, and no formal comparisons were
made. OS and PFS were estimated using Kaplan–Meier curves.
Treatment responses were described by treatment line and depth
of response, and patient characteristics were summarized using
descriptive statistics.
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